LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics

By LabMedica International staff writers
Posted on 26 Jan 2024
Print article
Image: The OneSystem strategic collaboration signing ceremony between Seegene and Microsoft took place in London, UK, on January 23 (Photo courtesy of Seegene)
Image: The OneSystem strategic collaboration signing ceremony between Seegene and Microsoft took place in London, UK, on January 23 (Photo courtesy of Seegene)

Seegene, Inc. (Seoul, Korea) and Microsoft (Redmond, WA, USA) have entered into a strategic collaboration that opens up a new chapter in the field of molecular diagnostics to realize 'a world free from all diseases and future pandemics'.

Seegene has selected Microsoft as a technology partner for its SG OneSystem business to realize 'a world free from all diseases.' By collaborating with Microsoft to drive the growth of its SG OneSystem business, Seegene has adopted an unprecedented strategy of sharing its unique syndromic quantitative PCR technologies with the world’s leading companies to encourage cross-industry innovation in molecular diagnostics. The expansion of participating companies, with whom Seegene aims to form a global consortium, will empower countries across the world with optimal solutions, enabling them to effectively address future pandemics and collectively move closer to 'a world free from all diseases.'

To achieve this goal, Seegene will work with Microsoft's global healthcare team to help further SG OneSystem's growth by advocating the collective vision, bridging potential partners, and jointly participating in SG OneSystem's annual symposium. Other key events connecting current and prospective SG OneSystem partners, such as a declaration ceremony for scientific communities and other partners participating in the SG OneSystem business will be held within the first half of this year to commemorate the shared vision. Seegene's Digitalized Development System (SGDDS) will integrate Microsoft Azure services, including Azure OpenAI Service, which will be used by Seegene to handle the landscape of data interaction and analysis for researchers dealing with extensive data generated by the SGDDS. The implementation of the highly secure and compliant Azure Trusted Research Environment (TRE) will push the boundaries of PCR research, helping ensure both privacy and regulatory adherence.

Seegene will implement Microsoft Fabric, a single AI-powered analytics platform that will unify Seegene's data and reshape how everyone accesses, manages, and acts on that data with capabilities that span data integration, data engineering, data science, data monitoring, real-time analytics, and business intelligence. The integration of AI-driven assistance through Copilot for Microsoft 365 is expected to accelerate productivity, foster innovation and enhance creativity. Furthermore, Seegene will collaborate with Microsoft on collective healthcare innovation research, including next-generation management and analytics for PCR data, and explore future ventures within the healthcare sector. Seegene aims to improve the healthcare ecosystem with Microsoft by delivering accurate early disease diagnoses that provide the foundation for effective treatment and prevention.

"The strategic collaboration with Microsoft will allow us to have a more structured SG OneSystemTM business model," said Dr. Jong-Yoon Chun, CEO and founder of Seegene. "Through our joint efforts, we expect synergetic effects to pave the way for a world free from all diseases."

"We support Seegene's vision of realizing 'a world free from all diseases,'" added Elena Bonfiglioli, General Manager, Global Health and Life Sciences at Microsoft. "In addition to working with Seegene on its digital transformation, we will collaborate to discover global partners and to further enhance the healthcare ecosystem."

Related Links:
Seegene, Inc.
Microsoft

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more